دورية أكاديمية
أعرض في EDS

Prevalence of dermatitis including allergic contact dermatitis from medical devices used by children and adults with Type 1 diabetes mellitus: A systematic review and questionnaire study.

التفاصيل البيبلوغرافية
العنوان: Prevalence of dermatitis including allergic contact dermatitis from medical devices used by children and adults with Type 1 diabetes mellitus: A systematic review and questionnaire study.
المؤلفون: von Kobyletzki LB; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.; School of Medical Sciences, Örebro University, Örebro, Sweden., Ulriksdotter J; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Sukakul T; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Aerts O; Contact Allergy Unit, Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, University of Antwerp, Antwerp, Belgium., Agner T; Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark., Buhl T; Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany., Bruze M; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Foti C; Section of Dermatology, DIMEPREJ Department, University 'Aldo Moro', Bari, Italy., Gimenez-Arnau A; Department of Dermatology, Hospital del Mar and Research Institute de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain., Gonçalo M; Clinic of Dermatology, Coimbra University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Hamnerius N; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Johansen JD; Department of Dermatology, Herlev and Gentofte Hospital, Copenhagen, Denmark., Rustemeyer T; Dermato-Allergology and Occupational Dermatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Stingeni L; Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Wilkinson M; Leeds Teaching Hospitals, NHS Trust, Leeds, UK., Svedman C; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.
المصدر: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jul; Vol. 38 (7), pp. 1329-1346. Date of Electronic Publication: 2024 Feb 23.
نوع المنشور: Journal Article; Systematic Review; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
مواضيع طبية MeSH: Diabetes Mellitus, Type 1*/complications , Diabetes Mellitus, Type 1*/epidemiology , Dermatitis, Allergic Contact*/epidemiology , Dermatitis, Allergic Contact*/etiology , Dermatitis, Allergic Contact*/diagnosis, Humans ; Prevalence ; Child ; Adult ; Blood Glucose Self-Monitoring/instrumentation ; Insulin Infusion Systems/adverse effects ; Surveys and Questionnaires ; Incidence
مستخلص: Use of medical devices (MDs), that is, glucose sensors and insulin pumps, in patients with Type 1 diabetes mellitus (T1D) has proven an enormous advantage for disease control. Adverse skin reactions from these MDs may however hamper compliance. The objective of this study was to systematically review and analyse studies assessing the prevalence and incidence of dermatitis, including allergic contact dermatitis (ACD) related to MDs used in patients with T1D and to compare referral routes and the clinical investigation routines between clinics being part of the European Environmental and Contact Dermatitis Research Group (EECDRG). A systematic search of PubMed, EMBASE, CINAHL and Cochrane databases of full-text studies reporting incidence and prevalence of dermatitis in persons with T1D using MDs was conducted until December 2021. The Newcastle-Ottawa Scale was used to assess study quality. The inventory performed at EECRDG clinics focused on referral routes, patient numbers and the diagnostic process. Among the 3145 screened abstracts, 39 studies fulfilled the inclusion criteria. Sixteen studies included data on children only, 14 studies were on adults and nine studies reported data on both children and adults. Participants were exposed to a broad range of devices. Skin reactions were rarely specified. It was found that both the diagnostic process and referral routes differ in different centres. Further data on the prevalence of skin reactions related to MDs in individuals with T1D is needed and particularly studies where the skin reactions are correctly diagnosed. A correct diagnosis is delayed or hampered by the fact that, at present, the actual substances within the MDs are not declared, are changed without notice and the commercially available test materials are not adequately updated. Within Europe, routines for referral should be made more standardized to improve the diagnostic procedure when investigating patients with possible ACD from MDs.
(© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
References: International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels, Belgium: IDF; 2021 [cited 2022 Oct 16]. Available from: https://www.diabetesatlas.org.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability‐adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223. Erratum in: Lancet 2013;381(9867):628. https://doi.org/10.1016/S0140‐6736(12)61689‐4.
Thomas M, Brownlee M, Susztak K, Sharma K, Jandeleit‐Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
Crasto W, Patel V, Davies MJ, Khunti K. Prevention of microvascular complications of diabetes. Endocrinol Metab Clin North Am. 2021;50(3):431–455.
Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med. 2021;38(5):e14528.
Nimri R, Nir J, Phillip M. Insulin pump therapy. Am J Ther. 2020;27(1):e30–e41.
Nationella Diabetesregistret ‐ Årsrapport 2021 års resultat. [cited 2022 Oct 16]. Available from: https://www.ndr.nu/#/arsrapport.
Berg AK, Nørgaard K, Thyssen JP, Zachariae C, Hommel E, Rytter K, et al. Skin problems associated with insulin pumps and sensors in adults with type 1 diabetes: a cross‐sectional study. Diabetes Technol Ther. 2018;20:475–482.
Berg AK, Olsen BS, Thyssen JP, Zachariae C, Simonsen AB, Pilgaard K, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes. 2018;19:733–740.
Herman A, Aerts O, Baeck M, Bruze M, De Block C, Goossens A, et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor. Contact Dermatitis. 2017;77(6):367–373.
Raison‐Peyron N, Mowitz M, Bonardel N, Aerts O, Bruze M. Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump. Contact Dermatitis. 2018;79(2):76–80.
Mowitz M, Herman A, Baeck M, Isaksson M, Antelmi A, Hamnerius N, et al. N,N‐dimethylacrylamide‐a new sensitizer in the FreeStyle Libre glucose sensor. Contact Dermatitis. 2019;81(1):27–31. https://doi.org/10.1111/cod.13243.
Herman A, Baeck M, de Montjoye L, Bruze M, Giertz E, Goossens A, et al. Allergic contact dermatitis caused by isobornyl acrylate in the Enlite glucose sensor and the Paradigm MiniMed Quick‐set insulin infusion set. Contact Dermatitis. 2019;81(6):432–437. https://doi.org/10.1111/cod.13374.
Hamnerius N, Mowitz M. Intense skin reaction to a new glucose monitoring and insulin pump system. Contact Dermatitis. 2020;83(6):524–527.
Christensen MO, Berg AK, Rytter K, Hommel E, Thyssen JP, Svensson J, et al. Skin problems due to treatment with technology are associated with increased disease burden among adults with type 1 diabetes. Diabetes Technol Ther. 2019;21(4):215–221.
Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152(5):622–628.
Eastman RC, Chase HP, Buckingham B, Hathout EH, Fuller‐Byk L, Leptien A, et al. Use of the GlucoWatch® biographer in children and adolescents with diabetes. Pediatr Diabetes. 2002;3(3):127–134.
Herman A, Darrigade AS, de Montjoye L, Baeck M. Contact dermatitis caused by glucose sensors in diabetic children. Contact Dermatitis. 2020;82(2):105–111.
Lombardo F, Passanisi S, Tinti D, Messina MF, Salzano G, Rabbone I. High frequency of dermatological complications in children and adolescents with type 1 diabetes: a web‐based survey. J Diabetes Sci Technol. 2021;15(6):1377–1381.
Vergier J, Samper M, Dalla‐Vale F, Ventura V, Baucher F, Joubert F, et al. Evaluation of flash glucose monitoring after long‐term use: a pediatric survey. Prim Care Diabetes. 2019;13(1):63–70.
Vidal‐Albareda C, Yelmo‐Valverde R, Solórzano‐Zepeda C, Rodríguez‐Muñoz N, de‐la‐Hoz‐Caballer B, González‐de‐Olano D. Prevalence of contact dermatitis to glucose sensors in pediatric population and the main allergens involved. Contact Dermatitis. 2020;83(1):47–49.
Schober E, Rami B. Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool‐age and school‐age children. Pediatr Diabetes. 2009;10(3):198–201.
Binder E, Lange O, Edlinger M, Meraner D, Abt D, Moser C, et al. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2015;123(4):260–264.
Hyry HSI, Liippo JP, Virtanen HM. Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients. Contact Dermatitis. 2019;81(3):161–166.
Rigo RS, Levin LE, Belsito DV, Garzon MC, Gandica R, Williams KM. Cutaneous reactions to continuous glucose monitoring and continuous subcutaneous insulin infusion devices in type 1 diabetes mellitus. J Diabetes Sci Technol. 2021;15(4):786–791.
Al Hayek AA, Robert AA, Al Dawish MA. Skin‐related complications among adolescents with type 1 diabetes using insulin pump therapy. Clin Med Insights Endocrinol Diabetes. 2018;11:1179551418798794.
Bolinder J, Antuna R, Geelhoed‐Duijvestijn P, Kroger J, Weitgasser R. Novel glucose‐sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non‐masked, randomised controlled trial. Lancet. 2016;388(10057):2254–2263.
Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long‐term safety, efficacy and side‐effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin‐dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989;32(7):421–426.
Charleer S, De Block C, Van Huffel L, Broos B, Fieuws S, Nobels F, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real‐world cohort study. Diabetes Care. 2020;43(2):389–397.
Chase HP, Beck R, Tamborlane W, Buckingham B, Mauras N, Tsalikian E, et al. A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care. 2005;28(5):1101–1106.
Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347–2359.
Garg SK, Smith J, Beatson C, Lopez‐Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009;11(2):65–72.
Grimm JJ, Haardt MJ, Thibult N, Goicolea I, Tchobroutsky G, Slama G. Lifestyle, metabolic control and social implications of pump therapy in 54 routine type I diabetic patients. Diabete Metab. 1987;13(1):3–11.
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections the gold randomized clinical trial. JAMA. 2017;317(4):379–387. Erratum in: JAMA. 2017;317(18):1912.
Mastrototaro JJ, Cooper KW, Soundararajan G, Sanders JB, Shah RV. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study. Adv Ther. 2006;23(5):725–732.
Oskarsson P, Antuna R, Geelhoed‐Duijvestijn P, Kroger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre‐specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61(3):539–550.
Pfutzner A, Sachsenheimer D, Grenningloh M, Heschel M, Walther‐Johannesen L, Gharabli R, et al. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: results from a prospective randomized crossover study. J Diabetes Sci Technol. 2015;9(6):1292–1298.
Šoupal J, Petruželková L, Grunberger G, Hásková A, Flekač M, Matoulek M, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow‐up from the comisair study. Diabetes Care. 2020;43(1):37–43.
Thrasher J, Surks H, Nowotny I, Pierre S, Rotthaeuser B, Wernicke‐Panten K, et al. Safety of insulin lispro and a biosimilar insulin lispro when administered through an insulin pump. J Diabetes Sci Technol. 2018;12(3):680–686.
Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics. 2003;111(4 Pt 1):790–794.
Diabetes Research in Children Network Study Group, Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, et al. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007;151(4):388–393.
Edge J, Acerini C, Campbell F, Hamilton‐Shield J, Moudiotis C, Rahman S, et al. An alternative sensor‐based method for glucose monitoring in children and young people with diabetes. Arch Dis Child. 2017;102(6):543–549.
Giani E, Macedoni M, Barilli A, Petitti A, Mameli C, Bosetti A, et al. Performance of the flash glucose monitoring system during exercise in youth with type 1 diabetes. Diabetes Res Clin Pract. 2018;146:321–329.
Massa GG, Gys I, Bevilacqua E, Wijnands A, Zeevaert R. Comparison of flash glucose monitoring with real time continuous glucose monitoring in children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2019;152:111–118.
Rachmiel M, Levy‐Shraga Y, Gruber N, Pinhas‐Hamiel O, Barash G, Pivko‐Levy D, et al. Comparing insulin pump devices in real life: the AWeSoMe study group prospective experience. Diabetes Technol Ther. 2019;21(3):138–145.
Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey TS, et al. Accuracy of a fourth‐generation continuous glucose monitoring system in children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2018;20(9):576–584.
Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, et al. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes. 2012;13(4):301–307.
Bozzetti V, Viscardi M, Bonfanti R, Azzinari A, Meschi F, Bognetti E, et al. Results of continuous glucose monitoring by Gluco Watch® Biographer in a cohort of diabetic children and adolescents under real‐life conditions. Pediatr Diabetes. 2003;4(1):57–58.
Landau Z, Abiri S, Gruber N, Levy‐Shraga Y, Brener A, Lebenthal Y, et al. Use of flash glucose‐sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real‐life observational experience. Acta Diabetol. 2018;55(12):1303–1310.
Messer LH, Calhoun P, Buckingham B, Wilson DM, Hramiak I, Ly TT, et al. In‐home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes. Pediatr Diabetes. 2017;18(5):332–339.
Weng AT, Zachariae C, Christensen KB, Svensson J, Berg AK. Five‐month follow‐up shows no improvement in dermatological complications in children with type 1 diabetes using continuous glucose monitoring systems and insulin pumps. J Diabetes Sci Technol. 2021;15(2):317–323.
Pyl J, Dendooven E, Van Eekelen I, den Brinker M, Dotremont H, France A, et al. Prevalence and prevention of contact dermatitis caused by FreeStyle Libre: a monocentric experience. Diabetes Care. 2020;43(4):918–920.
Deiss D, Irace C, Carlson G, Tweden KS, Kaufman FR. Real‐world safety of an implantable continuous glucose sensor over multiple cycles of use: a post‐market registry study. Diabetes Technol Ther. 2020;22(1):48–52.
Deshmukh H, Wilmot EG, Gregory R, Barnes D, Narendran P, Saunders S, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes‐related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care. 2020;43(9):2153–2160.
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of flash glucose‐sensing technology for 12 months as a replacement for blood glucose monitoring in insulin‐treated type 2 diabetes. Diabetes Ther. 2017;8(1):55–73.
Ramirez‐Rincon A, Hincapie‐García J, Arango CM, Aristizabal N, Castillo E, Hincapie G, et al. Clinical outcomes after 1 year of augmented insulin pump therapy in patients with diabetes in a specialized diabetes center in Medellín, Colombia. Diabetes Technol Ther. 2016;18(11):713–718.
Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S, Cygnus Research Team. Clinical evaluation of the GlucoWatch biographer: a continual, non‐invasive glucose monitor for patients with diabetes. Biosens Bioelectron. 2001;16(9–12):621–629.
Hoss U, Budiman ES, Liu H, Christiansen MP. Continuous glucose monitoring in the subcutaneous tissue over a 14‐day sensor wear period. J Diabetes Sci Technol. 2013;7(5):1210–1219.
Johansen JD, Bonefeld CM, Schwensen JFB, Thyssen JP, Uter W. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149(4):1162–1171.
Dotterud LK, Falk ES. Contact allergy in relation to hand eczema and atopic diseases in north Norwegian schoolchildren. Acta Paediatr. 1995;84(4):402–406. https://doi.org/10.1111/j.1651‐2227.1995.tb13659.x.
Ulriksdotter J, Mowitz M, Svedman C, Bruze M. Patch testing and diagnosis when suspecting allergic contact dermatitis from medical devices. Contact Dermatitis. 2020;83(4):333–335.
Ahrensbøll‐Friis U, Simonsen AB, Zachariae C, Thyssen JP, Johansen JD. Contact dermatitis caused by glucose sensors, insulin pumps, and tapes: results from a 5‐year period. Contact Dermatitis. 2021;84:75–81.
Isaksson M, Lindberg M, Sundberg K, Hallander A, Bruze M. The development and course of patch‐test reactions to 2‐hydroxyethyl methacrylate and ethyleneglycol dimethacrylate. Contact Dermatitis. 2005;53:292–297.
Goon AT, Bruze M, Zimerson E, Goh CL, Soo‐Quee Koh D, Isaksson M. Screening for acrylate/methacrylate allergy in the baseline series: our experience in Sweden and Singapore. Contact Dermatitis. 2008;59:307–313.
Ulriksdotter J, Svedman C, Bruze M, Glimsjö J, Källberg K, Sukakul T, et al. Contact dermatitis caused by glucose sensors ‐ 15 adult patients tested with a medical device patch test series. Contact Dermatitis. 2020;83:301–309.
Herman A, Uter W, Rustemeyer T, Matura M, Aalto‐Korte K, Duus Johansen J, et al. Position statement: the need for EU legislation to require disclosure and labelling of the composition of medical devices. J Eur Acad Dermatol Venereol. 2021;35(7):1444–1448. https://doi.org/10.1111/jdv.17238.
تواريخ الأحداث: Date Created: 20240224 Date Completed: 20240626 Latest Revision: 20240626
رمز التحديث: 20240626
DOI: 10.1111/jdv.19908
PMID: 38400603
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-3083
DOI:10.1111/jdv.19908